Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study
| Autor: | Matteo Megna, Giuseppe Argenziano, Genoveffa Scotto di Luzio, Nicola Balato, Francesco Cusano, Raffaele Mozzillo, Alessio Gambardella, Luisa Di Costanzo, Paola Colasanti, Antonia G Galluccio, Anna Balato, Gabriella Fabbrocini, Serena Lembo |
|---|---|
| Přispěvatelé: | Megna, M., Di Costanzo, L., Argenziano, G., Balato, A., Colasanti, P., Cusano, F., Galluccio, A. G., Gambardella, A., Lembo, S., Mozzillo, R., Scotto Di Luzio, G., Fabbrocini, G., Balato, N., Megna, Matteo, Di Costanzo, Luisa, Argenziano, Giuseppe, Balato, Anna, Colasanti, Paola, Cusano, Francesco, Galluccio, Antonia G, Gambardella, Alessio, Lembo, Serena, Mozzillo, Raffaele, Scotto Di Luzio, Genoveffa, Fabbrocini, Gabriella, Balato, Nicola |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine Pediatrics medicine.medical_specialty Clinical Biochemistry Treatment outcome Antibodies Monoclonal Humanized Antibodies Young Adult 03 medical and health sciences 0302 clinical medicine real life Psoriasis Monoclonal Drug Discovery medicine Treatment persistence Humans Young adult biologic drugs Humanized Retrospective Studies psoriasi Pharmacology business.industry secukinumab Follow up studies PASI Retrospective cohort study psoriasis Middle Aged medicine.disease Treatment Outcome 030104 developmental biology Anti-IL-17 Female Follow-Up Studies Italy 030220 oncology & carcinogenesis Long term data Secukinumab business biologic drug |
| Popis: | Background: Long term data on the real-life use of secukinumab are scant. The aim of this study was to investigate the real-life effectiveness, safety and treatment persistence of secukinumab in patients with moderate-to-severe psoriasis. Research design and methods: This 84-week, multicenter (n=7) retrospective study analyzed data from patients who initiated and received at least 6months of secukinumab treatment between June 2016 and June 2018 in the Campania region of Italy. Patient demographic and treatment characteristics, duration of treatment and reasons for discontinuation as well as Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Dermatology Life Quality Index (DLQI) scores were assessed. Results: 324 patients (63% male, mean age 50.2years) were enrolled and received a mean 11.7months of secukinumab treatment. Overall, 9.5% discontinued secukinumab, including 5.2% who discontinued due to secondary inefficacy and 1.8% due to adverse events. PASI, BSA and DLQI scores were significantly improved from baseline at every follow-up visit (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|